logo 2
Novel disease-modifying therapies: transforming the life of people suffering from CNS diseases
Read more
At Welab, we believe that partnership
in biomedical innovation has the potential to bring
innovative treatments to patients

Welab Barcelona is the World Leader in Drug Discovery and Development targeting Sigma receptors. We aim to create the next generation of disease modifying therapies to reverse CNS diseases and neuronal loss.

We are a patient centric company focused on drug innovation and partnered development, with a strong pipeline of oral medicines, created with world class chemistry and exclusively targeting diseases of the CNS, with optimized receptor pharmacology and a truly differentiated understanding of the neurocircuitry.

Read more

Welab's pipeline has multiple mid-term value inflections

Barra_Pipeline
Sigma-2
Sigma-1
Sigma-2 + Sigma-1
Sigma-1 multimodal synergistic
Sigma-1 multimodal synergistic
Alpha2Delta-1 selective
Sigma-1 + NET
Sigma-1 + biased Mu-Opioid partial agonist
Undisclosed targets
LPARx
NomsProjectesPipeline1
Read more